Pharmaceutical - Antibiotics and Infectious diseases, Oncology


Popular Filters

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer


Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California


MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

HedgePath Pharma to repurpose antifungal drug as cancer inhibitor


USA-based clinical stage biopharma company HedgePath Pharmaceuticals has announced plans to repurpose…

Antibiotics and Infectious diseasesHedgePath PharmaceuticalsitraconazoleMayne PharmaOncologyPharmaceuticalResearchSUBA-Itraconazole

Ukraine government introduces compulsory licensing for pharma products

Ukraine government introduces compulsory licensing for pharma products


Leading global pharmaceutical producers may suffer significant losses in Ukraine, as the country’s…

Anti-viralsAntibiotics and Infectious diseasesEastern EuropeLicensingOncologyPatentsPharmaceuticalUkraine

Four medicines recommended for approval by EMA/CHMP

Four medicines recommended for approval by EMA/CHMP


Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products…

AlconAntibiotics and Infectious diseasesComtriqDermatologicalsEuropeGaldermaJanssen-CilagJohnson & JohnsonMirvasoNovartisOncologyOphthalmicsPharmaceuticalRegulationSirturoTMC Pharma Services

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

Eisai takes over marketing authorization for Gliadel, and joins TB partnership


Japanese drug major Eisai (TYO: 4523) will become the Marketing Authorization Holder for the antineoplastic…

Antibiotics and Infectious diseasesAsia-PacificEisaiGliadelLicensingNobelpharmaOncologyPharmaceutical

Venus gets GMP certifications from Ukraine


Indian R&D-based drugmaker Venus Remedies (BSE: 526953) has been able to gain a Good Manufacturing Practice…

Antibiotics and Infectious diseasesAsia-PacificEuropeMarkets & MarketingOncologyPharmaceuticalProductionRegulationVenus Remedies

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone


US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

Breakthrough status for Pfizer's palbociclib; Merck & Co Noxafil NDA accepted


Global pharma behemoth Pfizer (NYSE: PFE) is the latest to gain a "Breakthrough Therapy" designation…

Antibiotics and Infectious diseasesMerck & CoNorth AmericaNoxafilOncologypalbociclibPfizerPharmaceuticalRegulation

Preliminary NICE guidance negative on Pfizer's Xalkori for lung cancer; backs Colobreathe and Tobi Podhaler for CF


Much to the disappointment of the company, this morning (March 27), UK drugs watchdog the National Institute…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisOncologyPfizerPharmaceuticalPricingRare diseasesRegulationTobi PodhalerXalkori

SOBI gains distribution rights for Megace, Monopril, Cefzil and Duricef from PharmaSwiss


Swedish Orphan Biovitrum (STO: SOBI) says that it has entered into a distribution agreement with privately-held…

Antibiotics and Infectious diseasesCardio-vascularCefzilDuricefEuropeLicensingMegaceMonoprilOncologyPharmaceuticalPharmaSwissSobiSwedish Orphan Biovitrum

Pharmstandard to produce Janssen's anti-TB drugs in Russia; Nyuvak deal


JSC Pharmstandard (PHST: MM), one of Russia's largest pharmaceutical producers, has signed an agreement…

Antibiotics and Infectious diseasesbedaquilineEuropeJanssenJohnson & JohnsonMarkets & MarketingNyuvakOncologyPharmaceuticalPharmstandardProductionquisinostat

US FDA approvals for Signifor, raxibacumab and Iclusig


In a flurry of activity from the US Food and Drug Administration on Friday, the agency - which looks…

Antibiotics and Infectious diseasesAriad PharmaceuticalsGlaxoSmithKlineIclusigNorth AmericaNovartisOncologyPharmaceuticalRare diseasesraxibacumabRegulationSignifor

India's Macleods Pharma to invest $25 million in production in Russia; Ferring to start manufacturing


Indian drugmaker Macleods plans to invest up to 700 million roubles (around $25 million) in the construction…

Antibiotics and Infectious diseasesEuropeFerring PharmaceuticalsGenericsIzvarino PharmaMacleods PharmaceuticalsOncologyPharmaceuticalProduction

Common antifungal drug thiabendazole shows promise as cancer therapy


An inexpensive US Food and Drug Administration approved antifungal drug, thiabendazole, slows tumor growth…

Antibiotics and Infectious diseasesOncologyPharmaceuticalResearchthiabendazole

Boehringer Ingelheim links with Harvard for unmet medical needs research


Family-controlled German drug major Boehringer Ingelheim has established a translational research collaboration…

Antibiotics and Infectious diseasesBoehringer IngelheimOncologyPharmaceuticalResearch

News briefs: GlaxoSmithKline and Bayer


UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

ViroPharma stock plunges on bad news for Vancocin; Sanofi patents invalidated


ViroPharma I (Nasdaq: VPHM) saw its shares plunge 19% to $23.25 yesterday after it announced that the…

Antibiotics and Infectious diseasesApotexGenericsHospiraLegalNorth AmericaOncologyPatentsPharmaceuticalRegulationSanofiTaxotereVancocinViroPharmaWatson Pharmaceuticals

Backing for Japanese approval of Regnite, Ranmark and Cancidas


USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it…

Antibiotics and Infectious diseasesAsia-PacificCancidasDaiichi SankyodenosumabHorizantMerck & CoOncologyPharmaceuticalRegniteRegulationXenoPort



Back to top